<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742869</url>
  </required_header>
  <id_info>
    <org_study_id>HITA</org_study_id>
    <nct_id>NCT03742869</nct_id>
  </id_info>
  <brief_title>HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma</brief_title>
  <official_title>A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma
      patients with and without human papillomavirus (HPV) infections. The multi-omics profiles
      include genome wide association study (GWAS), whole exome sequencing, analysis of
      transcriptomics and metabolomics. The HPV integration status is interpreted by GWAS. A
      comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism
      of tumorigenesis and prognosis of uterine cervical adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2018</start_date>
  <completion_date type="Anticipated">November 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequencies of somatic driving mutations</measure>
    <time_frame>Two years</time_frame>
    <description>The differences of frequencies of somatic driving mutations will be compared between patients with and without HPV integration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequencies of alteration of RNA expression</measure>
    <time_frame>Two years</time_frame>
    <description>The alteration of patterns of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients with and without HPV integration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of alteration of protein expression and signal pathway</measure>
    <time_frame>Two years</time_frame>
    <description>The alteration of patterns of protein expression and signal pathway will be compared between patients with and without HPV integration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>Progression-free survival between patients with differential expressed multi-omics will be compared.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Human Papillomavirus</condition>
  <condition>Genome-wide Association Study</condition>
  <condition>Whole Exome Sequencing</condition>
  <condition>Transcriptome</condition>
  <condition>Metabolome</condition>
  <condition>Tumorigenesis</condition>
  <condition>Prognosis</condition>
  <arm_group>
    <arm_group_label>Patients with HPV integration</arm_group_label>
    <description>The HPV integration status will be checked by GWAS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without HPV integration</arm_group_label>
    <description>The HPV integration status will be checked by GWAS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>A multi-omics analysis</intervention_name>
    <description>A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.</description>
    <arm_group_label>Patients with HPV integration</arm_group_label>
    <arm_group_label>Patients without HPV integration</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      An 8 ml peripheral venous blood, and 50 Î¼L cancer tissue and tissue adjacent to cancer will
      be collected from eligible patients.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients confirmed primary adenocarcinoma of the uterine cervix
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed primary adenocarcinoma of the uterine cervix

          -  Signed an approved informed consents

          -  Feasible for biopsy

        Exclusion Criteria:

          -  Not meeting all of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>13911988831</phone>
    <phone_ext>86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>13911988831</phone>
      <phone_ext>86</phone_ext>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinogenesis</mesh_term>
    <mesh_term>Cell Transformation, Neoplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be available to all researchers.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>All data will be available to all researchers once related papers have been accepted publicly, and will be available for ever.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

